This technique reveals distinct responses to BCR::ABL1 inhibitors in chronic myeloid leukemia, suggesting personalized therapy may enhance treatment efficacy.
Chronic myeloid leukemia (CML) treatment employs several FDA-approved BCR::ABL1 tyrosine kinase inhibitors (TKIs) with distinct efficacy and side effects influenced by patient-specific factors. This study introduces a microfluidic cell culture...
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: